Négociation Medivir B - MEDIVIR CFD

Medivir (MVIR B) designs innovative and high-end pharmaceuticals aimed to treat cancer and related diseases. The company is focused on nucleotide science and protease research. The development is conducted both in-house and along with partners. The products designed within the strategic partnership are MIV-802, Xerclear, Simprevir Olysio. The most prominent internal products are Remetinostat, MIV-711, Birinapant, MIV-818, MIV-323. Apart from the European region, the company operates in the American, Canadian and Japanese markets. The company’s stock is listed on the NASDAQ Stockholm. To catch up with the latest Medivir share price, follow Capital.com.